Haleon plc (NYSE:HLN) Shares Sold by Invesco Ltd.

Invesco Ltd. trimmed its position in Haleon plc (NYSE:HLN) by 5.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,622,516 shares of the company’s stock after selling 89,660 shares during the period. Invesco Ltd.’s holdings in Haleon were worth $15,479,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sierra Ocean LLC acquired a new stake in shares of Haleon in the fourth quarter valued at $26,000. Versant Capital Management Inc lifted its stake in Haleon by 2,029.1% during the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock valued at $34,000 after purchasing an additional 3,348 shares during the last quarter. Geneos Wealth Management Inc. bought a new stake in Haleon during the fourth quarter worth approximately $35,000. Spire Wealth Management acquired a new position in Haleon in the fourth quarter worth approximately $39,000. Finally, Addison Advisors LLC increased its holdings in shares of Haleon by 28.7% in the fourth quarter. Addison Advisors LLC now owns 4,954 shares of the company’s stock valued at $47,000 after buying an additional 1,106 shares in the last quarter. 6.67% of the stock is owned by institutional investors.

Haleon Price Performance

Shares of HLN opened at $10.22 on Monday. The business’s 50-day moving average is $10.09 and its 200-day moving average is $9.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The company has a market capitalization of $46.16 billion, a price-to-earnings ratio of 30.06, a P/E/G ratio of 2.82 and a beta of 0.24. Haleon plc has a fifty-two week low of $8.12 and a fifty-two week high of $10.80.

Haleon (NYSE:HLN) last released its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. The company had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. Equities research analysts expect that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The company also recently declared a — dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be given a $0.1166 dividend. This is a positive change from Haleon’s previous — dividend of $0.05. The ex-dividend date is Friday, April 25th. This represents a dividend yield of 1.6%. Haleon’s dividend payout ratio (DPR) is currently 58.97%.

Analyst Ratings Changes

HLN has been the subject of several research reports. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Haleon in a research note on Monday, March 3rd. Sanford C. Bernstein downgraded Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Hsbc Global Res lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. HSBC reissued a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. Finally, Morgan Stanley lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Six research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.